Glibenclamide reverses cardiovascular abnormalities of Cantu syndrome driven by KATP channel overactivity

Authors

Conor McClenaghan, Washington University School of Medicine in St. Louis
Yan Huang, Washington University School of Medicine in St. Louis
Zihan Yan, Washington University School of Medicine in St. Louis
Theresa M Harter, Washington University School of Medicine in St. Louis
Carmen M Halabi, Washington University School of Medicine in St. Louis
Rod Chalk, University of Oxford
Attila Kovacs, Washington University School of Medicine in St. Louis
Gijs van Haaften, University Medical Center Utrecht
Maria S Remedi, Washington University School of Medicine in St. Louis
Colin G Nichols, Washington University School of Medicine in St. Louis

Journal

The Journal of Clinical Investigation

Publication Date

2020

Volume

130

Issue

3

First Page

1116

Last Page

1121

Document Type

Open Access Publication

DOI

10.1172/JCI130571

Rights and Permissions

Glibenclamide reverses cardiovascular abnormalities of Cantu syndrome driven by KATP channel overactivity. Conor McClenaghan, Yan Huang, Zihan Yan, Theresa M. Harter, Carmen M. Halabi, Rod Chalk, Attila Kovacs, Gijs van Haaften, Maria S. Remedi, Colin G. Nichols. Journal of Clinical Investigation. 2020;130(3):1116-1121. doi: 10.1172/JCI130571.

Recommended Citation

McClenaghan, Conor; Huang, Yan; Yan, Zihan; Harter, Theresa M; Halabi, Carmen M; Chalk, Rod; Kovacs, Attila; van Haaften, Gijs; Remedi, Maria S; and Nichols, Colin G, "Glibenclamide reverses cardiovascular abnormalities of Cantu syndrome driven by KATP channel overactivity." The Journal of Clinical Investigation. 130, 3. 1116 - 1121. (2020).
https://digitalcommons.wustl.edu/open_access_pubs/8966